Analystreport

Gemphire Therapeutics Inc. (NASDAQ: GEMP) had its "overweight" rating re-affirmed by analysts at Piper Jaffray Companies. They now have a $22.00 price target on the stock.

GEMPHIRE THERAPEUTICS INC COMMON  (GEMP) 
Last gemphire therapeutics inc common earnings: 5/9 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.gemphire.com